Together, we can transform the future of blood cancer care

More than 187,000 people in the United States are diagnosed with leukemia, lymphoma, or another type of blood cancer each year. Learn how your tax-deductible donations to blood cancer research at MSK bring hope for new cures and faster access to lifesaving treatments.

Three MSK blood cancer specialists look at a computer monitor.

Your support fuels breakthroughs

Donors help make MSK a leader in blood cancer research and care. U.S. News & World Report ranked us as the #2 cancer hospital in the country, and Charity Navigator gave us its highest rating. 

We’ve made significant progress in blood cancer research and care

  • The first bone marrow transplant to a patient from an unrelated donor took place at MSK over 50 years ago — a groundbreaking achievement.  
  • In 2024 alone, the FDA approved 11 drugs — including treatments for people with blood cancers — based on clinical trials in which MSK played a key role. 

And we’re creating even more hope for tomorrow

Fund the next discovery in blood cancer research and care. You can also donate in honor or memory of a loved one. 

Donate now

Dedicated to making a difference

Comedian and co-founder of Comedy vs Cancer Nick Kroll onstage at the New York City theater Jazz at Lincoln Center.
Comedy vs Cancer is MSK’s official comedy benefit show for blood cancer research and has raised more than $7 million to support MSK physician-scientists who are changing the landscape of blood cancer care.
Learn more
Michael Wolff in conversation with another person.
When renowned jazz musician Michael Wolff was diagnosed with histiocytic sarcoma, a rare blood cancer that affects about 300 people in the United States each year, MSK experts used genomic sequencing to find him a targeted treatment.
Read Michael’s story
Dr. Saad Usmani running the TCS New York City Marathon.
Dr. Saad Usmani is MSK’s Myeloma Service Chief. He joined MSK’s official running program, Fred’s Team, to take on the TCS New York City Marathon while raising money and awareness for myeloma, a type of blood cancer.
Why Dr. Usmani runs
Jennifer Brosnan wearing a Cycle for Survival shirt.
MSK employees Jennifer Brosnan and Dr. Santosha Vardhana channel their connection to blood cancers, which are all rare cancers, into making an impact through Cycle for Survival, MSK’s official rare cancer fundraiser.
Read more

Your gift today can power the next big breakthrough

With your support, MSK can continue leading the way in blood cancer research and care. Learn more about MSK’s innovations and advances and the progress you fuel as an MSK Giving donor.

Innovating in immunotherapy
Innovating in immunotherapy

MSK doctors helped lead a collaborative study that found that it may be possible to develop immunotherapy treatments for acute myeloid leukemia and myelodysplastic syndrome, two difficult-to-treat blood cancers.

Learn more
Training future leaders
Training future leaders

Donor support is essential to MSK’s world-leading education programs. Learn how recent graduates of the Gerstner Sloan Kettering Graduate School of Biomedical Sciences are advancing blood cancer research.

Meet the graduates
Creating hope for new cures
Creating hope for new cures

Multiple myeloma, a blood cancer, isn’t yet curable — but recent advances mean it can be managed for years. With donor support, MSK is driving research that brings us closer to a cure.

See the latest advances

Transform the future of blood cancer care worldwide

Donate now

More ways to make a difference

Give in honor or memory
Make your blood cancer donation personal with someone special in mind.
Donate now
Start a fundraiser
Invite your friends and family to join you in your mission.
Get started
Cycle for Survival
Cycle for Survival is the official rare cancer fundraiser for MSK. Join an exciting and inspiring event and support research with every dollar you raise.
Learn more
All ways to give
As an MSK donor, you can bring hope for new cures to people worldwide. Learn about the many ways you can support MSK’s mission.
See more